Right to Treat Act

Download PDF
Bill ID: 119/s/1830
Last Updated: April 5, 2026

Sponsored by

Sen. Johnson, Ron [R-WI]

ID: J000293

Follow the money

The bill

Right to Treat Act

S. 1830, 119th Congress — read as touching Pharmaceuticals.

The sponsor

Sen. Johnson, Ron [R-WI]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$96,068 raised

27 itemised contributions to this sponsor, pulled from FEC filings.

The alignment

63% match to Project 2025

This bill's text tracks the "Introduction" section, p. 497-499 of the Mandate for Leadership.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Committee on Health, Education, Labor, and Pensions. Hearings held.

March 18, 2026

Introduced

Committee Review

📍 Current Status

Next: The bill moves to the floor for full chamber debate and voting.

🗳️

Floor Action

Passed Senate

🏛️

House Review

🎉

Passed Congress

🖊️

Presidential Action

⚖️

Became Law

📚 How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

Another masterpiece of legislative lunacy, courtesy of the esteemed Senator Johnson and his cohorts in Congress. The "Right to Treat Act" - a bill so brazenly Orwellian, it's almost as if they're trying to make us laugh.

**Main Purpose & Objectives:** Ah, the stated purpose: to "clarify" that agencies within the Department of Health and Human Services (HHS) don't have the authority to regulate the practice of medicine. How noble. In reality, this bill is a thinly veiled attempt to gut regulatory oversight and give medical professionals carte blanche to prescribe whatever they want, whenever they want.

**Key Provisions & Changes to Existing Law:** Section 2(a)(1) explicitly strips HHS agencies, including the FDA, NIH, and CDC, of their authority to regulate medicine. But wait, there's more! Section 2(a)(2) allows doctors to prescribe approved drugs for unapproved uses without restriction. Because what could possibly go wrong with that? The cherry on top is the "Rule of Construction" in Section 2(b), which ensures this bill won't affect laws restricting abortion, assisted suicide, or other sensitive topics - a clear attempt to appease the moral crusaders while still gutting regulatory oversight.

**Affected Parties & Stakeholders:** Medical professionals will love this bill, as it gives them unfettered freedom to prescribe whatever they want. Patients, on the other hand, might not be so thrilled about being guinea pigs for untested treatments. Pharmaceutical companies will likely rejoice at the prospect of increased sales and reduced regulatory scrutiny.

**Potential Impact & Implications:** This bill is a recipe for disaster. Without regulatory oversight, medical professionals can prescribe whatever they want, regardless of efficacy or safety. Patients will be exposed to unproven treatments, and pharmaceutical companies will reap the benefits. It's a perfect storm of greed, recklessness, and incompetence.

Diagnosis: This bill suffers from a severe case of "Regulatory Capture Syndrome" - a disease where politicians prioritize special interests over public health and safety. The symptoms are clear: a complete disregard for evidence-based medicine, a blatant attempt to appease powerful lobbies, and a reckless abandonment of regulatory oversight.

Treatment: None needed. This bill is a lost cause. But hey, at least it'll make for some great case studies in the annals of legislative lunacy.

Related Topics

Healthcare & Insurance ReformPublic Health & Pandemic Response
Generated using Llama 3.1 70B (Dr. Haus personality)

💰 Campaign Finance Network

Sen. Johnson, Ron [R-WI]

Congress 119 • 2024 Election Cycle

Total Contributions
$96,068
21 donors
PACs
$0
Organizations
$933
Committees
$0
Individuals
$95,135

No PAC contributions found

1
RICHARD & PEGGY LARSEN FARMS
1 transaction
$500
2
SUNSET TRUST
2 transactions
$208
3
SOLE TERRA FARMING
1 transaction
$100
4
M AND M FARMS PARTNERSHIP
1 transaction
$50
5
TORK RENTALS
1 transaction
$50
6
FAITH CHRISTIAN CHURCH
1 transaction
$25

No committee contributions found

1
PECK, JOHN
4 transactions
$27,000
2
TAYLOR, MARGARETTA J.
1 transaction
$6,600
3
MANDELBLATT, DANIELLE
1 transaction
$6,600
4
MANDELBLATT, ERIC
1 transaction
$6,600
5
YANG, JIN
2 transactions
$6,600
6
BROWN, REGINALD J. MR.
2 transactions
$6,600
7
FEUERBACH, JOEL
1 transaction
$5,000
8
STANTON, FREDERICK
1 transaction
$4,800
9
PECK, VERA
1 transaction
$4,500
10
LATZIG, STEVE
1 transaction
$4,000
11
ROEHL, RICHARD
1 transaction
$3,500
12
LUTHER, JOSEPH
1 transaction
$3,435
13
EMERSON, BILL C. MR.
1 transaction
$3,300
14
WILKES, BRUCE
1 transaction
$3,300
15
MINER, JOHN R.
1 transaction
$3,300

Donor Network - Sen. Johnson, Ron [R-WI]

PACs
Organizations
Individuals
Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Loading...

Showing 46 nodes and 27 connections (61 secondary connections hidden)

Total contributions: $96,068

Top Donors - Sen. Johnson, Ron [R-WI]

Showing top 21 donors by contribution amount

6 Orgs15 Individuals

Industry Impact

Which industries are materially affected by specific provisions in this bill. 4 helped.

  • +Pharmaceuticalsconfidence 0.90

    Section 2(a)(2) prohibits federal agencies from restricting prescription or disbursement for unapproved use of any FDA-approved drug, expanding off-label use and benefiting pharmaceutical manufacturers.

  • Section 2(a)(1) removes authority of HHS agencies (including CDC, NIH, FDA) to regulate the practice of medicine, reducing regulatory burden on hospitals and health systems.

  • +Biotech & Researchconfidence 0.80

    Section 2(a)(2) allows unrestricted off-label use of FDA-approved drugs, which can increase demand for biologics and specialty drugs developed by biotech firms.

  • +Medical Devicesconfidence 0.75

    Section 2(a)(1) limits federal agency authority over the practice of medicine, which may reduce oversight of device use in clinical settings, benefiting device manufacturers.

Who funds the sponsor on these industries

For each industry this bill affects, here's what the sponsor (Sen. Johnson, Ron [R-WI])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.

Industries this bill HELPS

  • from 39 contributions
    • VOLLIN, SHYANNE$284
    • STALLWORTH, RAMONA$210
    • LEONARD, ANNE$165
    • HARFORD, DON$150
    • MCNEELY, MORGAN$70
  • from 12 contributions
    • EMERSON, PAMELA$610
    • FISCHER, STEVEN$100
    • MALKOWSKI, DENNIS$75
  • from 3 contributions
    • GIFFORD, LOUANN$50
    • KREKLAU, EMIKO$25
    • VANNEWKIRK, MYLAN$15

Project 2025 Policy Matches

This bill shows semantic similarity to the following sections of the Project 2025 policy document.

Introduction

Moderate63.4%
Pages: 497-499

— 464 — Mandate for Leadership: The Conservative Promise l The Risk Adjustment Data Validation (RADV) rule; l The Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) demonstration; and l The Global and Professional Direct Contracting (GPDC, rebranded as the Accountable Care Organization Realizing Equity, Access, and Community Health or ACO REACH) model. Additionally, regulations should advance site neutrality by eliminating the inpa- tient-only list and expanding the ambulatory surgical center covered procedures list. Medicare generally pays more for inpatient hospital procedures and less for the same procedures performed in an outpatient setting. Whether a medical ser- vice is delivered in a physician’s office, a clinic, or a hospital setting, the Medicare payment for that service should be the same. CMS should expand the application of site-neutral payment options to more settings. Such a policy would level the playing field among providers and remove the financial disabilities for medical professionals who would compete with hospital systems.23 Finally, HHS needs to restore and enhance conscience protection regulations that allow medical practitioners to participate in federal health care programs without being compelled to provide sex changes or similar services. LEGISLATIVE PROPOSALS l Remove restrictions on physician-owned hospitals. The Affordable Care Act (ACA)24 imposed restrictions prohibiting Medicare from reimbursing physician-owned and specialty hospitals. The current restrictions do little more than serve the special interests of large hospital systems and undercut consumer choice of high-quality, specialty care. These restrictions should be removed so that physician-owned hospitals can compete with other hospitals in serving Medicare patients.25 l Encourage more direct competition between Medicare Advantage and private plans. Medicare Advantage (MA), a system of competing private health plans, is the major alternative to traditional Medicare for America’s large and growing cohort of seniors. The program provides beneficiaries with a wide range of competitive health plan choices—a richer set of benefits than traditional Medicare provides and at a reasonable cost. Equally as important, the MA program has been registering consistently high marks for superior performance in delivering high-quality care. Critical reforms are still needed to strengthen and improve the program for the future. Specifically:

Introduction

Moderate63.4%
Pages: 497-499

— 464 — Mandate for Leadership: The Conservative Promise l The Risk Adjustment Data Validation (RADV) rule; l The Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) demonstration; and l The Global and Professional Direct Contracting (GPDC, rebranded as the Accountable Care Organization Realizing Equity, Access, and Community Health or ACO REACH) model. Additionally, regulations should advance site neutrality by eliminating the inpa- tient-only list and expanding the ambulatory surgical center covered procedures list. Medicare generally pays more for inpatient hospital procedures and less for the same procedures performed in an outpatient setting. Whether a medical ser- vice is delivered in a physician’s office, a clinic, or a hospital setting, the Medicare payment for that service should be the same. CMS should expand the application of site-neutral payment options to more settings. Such a policy would level the playing field among providers and remove the financial disabilities for medical professionals who would compete with hospital systems.23 Finally, HHS needs to restore and enhance conscience protection regulations that allow medical practitioners to participate in federal health care programs without being compelled to provide sex changes or similar services. LEGISLATIVE PROPOSALS l Remove restrictions on physician-owned hospitals. The Affordable Care Act (ACA)24 imposed restrictions prohibiting Medicare from reimbursing physician-owned and specialty hospitals. The current restrictions do little more than serve the special interests of large hospital systems and undercut consumer choice of high-quality, specialty care. These restrictions should be removed so that physician-owned hospitals can compete with other hospitals in serving Medicare patients.25 l Encourage more direct competition between Medicare Advantage and private plans. Medicare Advantage (MA), a system of competing private health plans, is the major alternative to traditional Medicare for America’s large and growing cohort of seniors. The program provides beneficiaries with a wide range of competitive health plan choices—a richer set of benefits than traditional Medicare provides and at a reasonable cost. Equally as important, the MA program has been registering consistently high marks for superior performance in delivering high-quality care. Critical reforms are still needed to strengthen and improve the program for the future. Specifically: — 465 — Department of Health and Human Services 1. Make Medicare Advantage the default enrollment option. 2. Give beneficiaries direct control of how they spend Medicare dollars. 3. Remove burdensome policies that micromanage MA plans. 4. Replace the complex formula-based payment model with a competitive bidding model. 5. Reconfigure the current risk adjustment model. 6. Remove restrictions on key benefits and services, including those related to prescription drugs, hospice care, and medical savings account plans.26 Legacy Medicare Reform. Legislation reforming legacy (non-MA) Medicare should: l Base payments on the health status of the patient or intensity of the service rather than where the patient happens to receive that service. l Replace the bureaucrat-driven fee-for-service system with value- based payments to empower patients to find the care that best serves their needs. l Codify price transparency regulations. l Restructure 340B drug subsidies27 toward beneficiaries rather than hospitals. l Repeal harmful health policies enacted under the Obama and Biden Administrations such as the Medicare Shared Savings Program28 and Inflation Reduction Act.29 Medicare Part D Reform. The Inflation Reduction Act (IRA) created a drug price negotiation program in Medicare that replaced the existing private-sector negotiations in Part D with government price controls for prescription drugs. These government price controls will limit access to medications and reduce patient access to new medication. This “negotiation” program should be repealed, and reforms in Part D that will have meaningful impact for seniors should be pursued. Other reforms should include eliminating the coverage gap in Part D, reducing the government share in

Introduction

Moderate61.0%
Pages: 506-508

— 473 — Department of Health and Human Services l Rewrite the ACA abortion separate payment regulation. Section 1303 of Obamacare requires that insurers collect a separate payment for certain abortion coverage in qualified health plans that are approved to be sold on exchanges and that they keep those separate payments in separate accounts that are used only to pay for elective abortion services. Neither the letter nor the spirit of the law was enforced under President Obama, and a Trump- era regulation sought to correct this problem. The Biden HHS rescinded this regulation to allow insurance companies once again—contrary to the law—to collect combined payments for what are clearly required to be separate payments for elective abortion coverage. “Separate” does not mean “together.” HHS should reinstate a Trump Administration regulation and enforce what the plain text of Section 1303 requires. That regulation should be further improved by requiring CMS to ensure that consumers pay truly separate charges for abortion coverage. l Audit Hyde Amendment compliance. HHS should undertake a full audit to determine compliance or noncompliance with the Hyde amendment and similar funding restrictions in HHS programs. This audit should include a full review of the Biden Administration’s post-Dobbs executive actions to promote abortion. It should also encompass a review of Medicaid managed care plans in pro-abortion states. l Reverse distorted pro-abortion “interpretations” added to the Emergency Medical Treatment and Active Labor Act. The Emergency Medical Treatment and Active Labor Act (EMTALA)52 prohibits hospitals that receive Medicare funds from “dumping” emergency patients who cannot pay by sending them to other hospitals. It also mandates that hospitals stabilize pregnant women and explicitly protects unborn children. Hospitals or physicians found to be in violation of the statute could lose all of their federal health funding—Medicare, Medicaid, CHIP, and other funds—and face civil penalties of up to nearly $120,000. In July 2022, HHS/CMS released guidance mandating that EMTALA- covered hospitals and the physicians who work there must perform abortions, to include completing chemical abortions even when the child might still be alive. The guidance also declared that EMTALA would protect physicians and hospitals that perform abortions in violation of state law if they deem those abortions necessary to stabilize the women’s health. This novel interpretation of EMTALA is baseless. EMTALA requires — 474 — Mandate for Leadership: The Conservative Promise no abortions, preempts no pro-life state laws, and explicitly requires stabilization of the unborn child. HHS should rescind the guidance and end CMS and state agency investigations into cases of alleged refusals to perform abortions. DOJ should agree to eliminate existing injunctions against pro-life states, withdraw its enforcement lawsuits, and in lawsuits against CMS on the guidance agree to injunctions against CMS and withdraw appeals of injunctions. l Reissue a stronger transgender national coverage determination. CMS should repromulgate its 2016 decision that CMS could not issue a National Coverage Determination (NCD) regarding “gender reassignment surgery” for Medicare beneficiaries. In doing so, CMS should acknowledge the growing body of evidence that such interventions are dangerous and acknowledge that there is insufficient scientific evidence to support such coverage in state plans. l Enforce EMTALA. The undeniable reality of abortion is that it does do not always result in a dead baby, and these born-alive babies are left to die. HHS should use EMTALA and Section 504 of the Rehabilitation Act,53 which prohibits disability discrimination, to investigate instances of infants born alive and left untreated in covered hospitals. CMS, OCR, and OIG should be required to follow through on these investigations with specific enforcement actions. HHS should revive a Trump Administration proposed regulation, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,”54 to achieve this end. In addition, Congress should pass the Born-Alive Abortion Survivors Protection Act55 to require that proper medical care be given to infants who survive an abortion and to establish criminal consequences for practitioners who fail to provide such care. l Permanently codify both the Hyde family of amendments and the protections provided by the Weldon Amendment. Congress can accomplish this through legislation such as the No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act56 (Hyde) and the Conscience Protection Act57 (Weldon).

Showing 3 of 4 policy matches

About These Correlations

Policy matches are calculated using semantic similarity between bill summaries and Project 2025 policy text. A score of 60% or higher indicates meaningful thematic overlap. This does not imply direct causation or intent, but highlights areas where legislation aligns with Project 2025 policy objectives.

Full Policy Text

Related Bills